Corvus Pharmaceuticals, Inc.

When one public company acquires another the conventional wisdom is that the stock prices of acquired and acquirer move in different directions. The most logical move is for the acquired company’s val

AstraZeneca PLC appears to have found two novel immuno-oncology partners that can improve outcomes when combined with its PD-L1 checkpoint inhibitor Imfinzi (durvalumab) without adding very much to t

The motto in venture capital investment for biopharmaceutical companies these days seems to be "go big or go home," with $100m-plus financings – often at the Series A stage – becoming more frequent an

There are many tales in the biotech sector of hundreds of millions of dollars being invested and then lost but the demise of Vernalis PLC , which in its various guises was a flag-bearer for the indus